---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-009767"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T11:02:41.429832+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Clearside reduces sublicense fees to high single digit; maintenance fees set $250K-$500K for 2023-2028

## Summary
- Sublicense percentage reduced from low double digits to high single digits for fees received from sublicensees.
- Maintenance fees: $250K for 2023-2025, $350K for 2026, $400K for 2027, $500K for 2028.
- 2023 maintenance fee of $250K due within 5 days of amendment execution (Jan 31, 2024).
- Reduced sublicense fee excludes R&D reimbursements, IP value transfers, and stock payments.
- Royalty rate on product sales remains unchanged at low single digit.

## SEC filing metadata
- accession: 0000950170-24-009767
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017024009767/0000950170-24-009767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017024009767/clsd-20240131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-009767
- JSON: https://secwatch.observer/filing/0000950170-24-009767.json
- Plain text: https://secwatch.observer/filing/0000950170-24-009767.txt

## Key facts
- Material Agreements
  Clearside Biomedical, Inc. amended License Agreement with Emory University valued at reduction of Sublicense Percentage from a low double digit to a high single digit; revised annual li (effective 2024-01-31).
  - Action: amendment
  - Agreement: license
  - Counterparty: Emory University
  - Value: reduction of Sublicense Percentage from a low double digit to a high single digit; revised annual li
  - Effective: 2024-01-31
  source text: On January 31, 2024 (the “ Amendment Execution Date ”), Clearside Biomedical, Inc. (the “ Company ”), Emory University (“ Emory ”) and Georgia Tech Research Corporation (together with Emory, the “ Licensor ”), entered into an amendment (the “ Amendment ”) to the Company’s License Agreement with Licensor dated July 4, 2012 (as amended, the “ License Agreement ”), pursuant to which the Company received a worldwide exclusive license to specified patents relating to methods and devices for drug delivery using a microinjector.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017024009767/0000950170-24-009767-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.